Scotland has become the first country in the UK to back NHS funding for the use of Merck & Co/MSD's Keytruda in combination with Eisai's Lenvima as a treatment for advanced or recurrent
UK medtech company Brainomix has secured backing from a UK government-funded agency for a year-long study of its artificial intelligence-powered platform to monitor patients with lung cance
Australian biotech Immutep's LAG-3 checkpoint inhibitor eftilagimod alpha (efti) may not be the first drug in the class to reach the market, but is a strong contender and, according to at l
Servier is already in the process of transforming itself into a much bigger player in cancer, and has just tripled its sales objectives for the category.
GSK's latecomer to the PD-1/PD-L1 inhibitor category Jemperli has barely started to bring in revenues, and is a world away from the company's hopes of blockbuster revenues by 2031.
The FDA has approved Swiss pharmaceutical company Roche’s first companion diagnostic for identifying those patients with HER2 low-metastatic breast cancer who are eligible for ENHERTU.